drugset / Trial / NCT03014479
Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the reduction in treatment burden during 12 weeks of trelagliptin administration in patients with type 2 diabetes on diet and exercise therapy only.
Timeline
- Start
- 2017-02-18
- Primary completion
- 2017-10-21
- Completion
- 2017-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alogliptin | Unknown | — | Oral |
| Comparator | Anagliptin | Small molecule | — | Oral |
| Comparator | Linagliptin | Small molecule | — | Oral |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | — | Oral |
| Comparator | Sitagliptin | Small molecule | — | Oral |
| Comparator | Teneligliptin | Small molecule | — | Oral |
| Subject | Trelagliptin | Small molecule | 50 mg | Oral |
| Subject | Trelagliptin | Small molecule | 100 mg | Oral |
| Comparator | Vildagliptin | Other / unclassified | — | Oral |